Strunk Sven Erik, Graf Johanna, Krakowczyk Julia Barbara, Wieser Alexandra, Heinen Jana, Schug PhD Caterina, Jahre Lisa Maria, Skoda Eva-Maria, Erim Yesim, Teufel Martin, Bäuerle Alexander
Clinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Essen, Germany.
Integr Cancer Ther. 2025 Jan-Dec;24:15347354251320047. doi: 10.1177/15347354251320047.
A large number of patients with cancer experience distress, but not all of them receive adequate psychological support. The e-psycho-oncological short-term intervention "By your Side" was developed to offer evidence-based and low-threshold support for cancer patients dealing with distress.
A longitudinal intervention pilot study was conducted from 4 March 2022 to 4 January 2023. N = 91 participants took part in the study. N = 82 completed the first module, while n = 23 successfully completed the whole intervention and were included in the final data analyses. "By your Side" consists of 16 modules based on cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction. Differences in distress between the baseline (T0), post-intervention (T1), and follow-up (T2) were analyzed using an ANCOVA and post-hoc -tests. Secondary outcomes (anxiety, depression, mindfulness, and self-efficacy) were also compared between measuring points, using ANOVAs and post-hoc tests.
A significant reduction ( = 0.014, = 0.654) in distress from baseline (T0, = 52.68, SD = 16.34) to follow-up (T2, = 43.84, SD = 17.59) was observed. There was a significant decrease in anxiety symptoms and a significant increase in mindfulness and self-efficacy. The user's satisfaction ( = 28.00, range 8-32) and the usability ( = 89.57, range 0-100) of the intervention were high.
The study provides preliminary evidence that the e-psycho-oncological short-term intervention "By your Side" can successfully reduce the distress of cancer patients. The high dropout rate (74.7%) must be taken into account.
German Clinical Trial Register (https://www.drks.de/search/de/trial/DRKS00036001), DRKS number: 00036001 (retrospectively registered).
大量癌症患者经历痛苦，但并非所有人都能获得足够的心理支持。电子心理肿瘤短期干预项目“伴你同行”旨在为应对痛苦的癌症患者提供循证且低门槛的支持。
于2022年3月4日至2023年1月4日进行了一项纵向干预试点研究。N = 91名参与者参与了该研究。N = 82人完成了第一个模块，而n = 23人成功完成了整个干预并被纳入最终数据分析。“伴你同行”由基于认知行为疗法、接纳与承诺疗法以及正念减压疗法的16个模块组成。使用协方差分析和事后检验分析基线（T0）、干预后（T1）和随访（T2）之间痛苦程度的差异。测量点之间还使用方差分析和事后检验比较了次要结果（焦虑、抑郁、正念和自我效能感）。
观察到从基线（T0， = 52.68，标准差 = 16.34）到随访（T2， = 43.84，标准差 = 17.59）痛苦程度显著降低（ = 0.014， = 0.654）。焦虑症状显著减少，正念和自我效能感显著增加。干预的用户满意度（ = 28.00，范围8 - 32）和可用性（ = 89.57，范围0 - 100）很高。
该研究提供了初步证据，表明电子心理肿瘤短期干预项目“伴你同行”能够成功减轻癌症患者的痛苦。必须考虑到高退出率（74.7%）。
德国临床试验注册中心（https://www.drks.de/search/de/trial/DRKS00036001），DRKS编号：00036001（追溯注册）。
